Shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) were up 3.1% during trading on Tuesday . The company traded as high as $11.12 and last traded at $11.00, with a volume of 117,094 shares traded. The stock had previously closed at $10.67.

A number of analysts recently commented on ESPR shares. Lake Street Capital lowered their price objective on Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, June 29th. Zacks Investment Research upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Tuesday, August 9th. Vetr upgraded Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and set a $12.60 target price for the company in a research report on Monday, July 25th. WallachBeth Capital lowered Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 target price for the company. in a research report on Tuesday, July 5th. Finally, JMP Securities restated a “buy” rating and set a $67.00 target price on shares of Esperion Therapeutics in a research report on Thursday, June 16th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company’s stock. Esperion Therapeutics presently has a consensus rating of “Hold” and an average target price of $24.40.

The company’s 50 day moving average is $10.95 and its 200-day moving average is $14.70. The stock’s market cap is $242.86 million.

Esperion Therapeutics (NASDAQ:ESPR) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.16. During the same period in the prior year, the company earned ($0.55) earnings per share. On average, equities analysts expect that Esperion Therapeutics Inc. will post ($3.36) earnings per share for the current fiscal year.

In other news, Director Mark E. Mcgovern bought 5,000 shares of the company’s stock in a transaction on Wednesday, July 6th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $50,000.00. Following the completion of the transaction, the director now owns 600 shares of the company’s stock, valued at $6,000. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.